Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2019 1
2020 24
2021 33
2022 3
Text availability
Article attribute
Article type
Publication date

Search Results

56 results
Results by year
Filters applied: . Clear all
Page 1
Recent advances of immunotherapy for biliary tract cancer.
Rizzo A, Ricci AD, Brandi G. Rizzo A, et al. Among authors: ricci ad. Expert Rev Gastroenterol Hepatol. 2021 May;15(5):527-536. doi: 10.1080/17474124.2021.1853527. Epub 2021 Jan 8. Expert Rev Gastroenterol Hepatol. 2021. PMID: 33215952 Review.
Experimental HER2- targeted therapies for biliary tract cancer.
Rizzo A, Ricci AD, Bonucci C, Tober N, Palloni A, Frega G, Brandi G. Rizzo A, et al. Among authors: ricci ad. Expert Opin Investig Drugs. 2021 Apr;30(4):389-399. doi: 10.1080/13543784.2021.1854724. Epub 2020 Dec 6. Expert Opin Investig Drugs. 2021. PMID: 33218269 Review.
Nivolumab: an investigational agent for the treatment of biliary tract cancer.
Di Federico A, Rizzo A, Ricci AD, Frega G, Palloni A, Tavolari S, Brandi G. Di Federico A, et al. Among authors: ricci ad. Expert Opin Investig Drugs. 2021 Apr;30(4):325-332. doi: 10.1080/13543784.2021.1863946. Epub 2020 Dec 23. Expert Opin Investig Drugs. 2021. PMID: 33307866 Review.
Second-line Treatment in Advanced Biliary Tract Cancer: Today and Tomorrow.
Rizzo A, Ricci AD, Tober N, Nigro MC, Mosca M, Palloni A, Abbati F, Frega G, DE Lorenzo S, Tavolari S, Brandi G. Rizzo A, et al. Among authors: ricci ad. Anticancer Res. 2020 Jun;40(6):3013-3030. doi: 10.21873/anticanres.14282. Anticancer Res. 2020. PMID: 32487595 Review.
56 results